Page Amy T, Clifford Rhonda M, Potter Kathleen, Schwartz Darren, Etherton-Beer Christopher D
School of Medicine and Pharmacology, University of Western Australia, 35 Stirling Highway, Crawley, 6009, Western Australia, Australia.
Graylands Hospital, Mt Claremont, Western Australia, Australia.
Br J Clin Pharmacol. 2016 Sep;82(3):583-623. doi: 10.1111/bcp.12975. Epub 2016 Jun 13.
Deprescribing is a suggested intervention to reverse the potential iatrogenic harms of inappropriate polypharmacy. The review aimed to determine whether or not deprescribing is a safe, effective and feasible intervention to modify mortality and health outcomes in older adults.
Specified databases were searched from inception to February 2015. Two researchers independently screened all retrieved articles for inclusion, assessed study quality and extracted data. Data were pooled using RevMan v5.3. Eligible studies included those where older adults had at least one medication deprescribed. The primary outcome was mortality. Secondary outcomes were adverse drug withdrawal events, psychological and physical health outcomes, quality of life, and medication usage (e.g. successful deprescribing, number of medications prescribed, potentially inappropriate medication use).
A total of 132 papers met the inclusion criteria, which included 34 143 participants aged 73.8 ± 5.4 years. In nonrandomized studies, deprescribing polypharmacy was shown to significantly decrease mortality (OR 0.32, 95% CI: 0.17-0.60). However, this was not statistically significant in the randomized studies (OR 0.82, 95% CI 0.61-1.11). Subgroup analysis revealed patient-specific interventions to deprescribe demonstrated a significant reduction in mortality (OR 0.62, 95% CI 0.43-0.88). However, generalized educational programmes did not change mortality (OR 1.21, 95% CI 0.86-1.69).
Although nonrandomized data suggested that deprescribing reduces mortality, deprescribing was not shown to alter mortality in randomized studies. Mortality was significantly reduced when applying patient-specific interventions to deprescribe in randomized studies.
减药是一种旨在逆转不适当联合用药潜在医源性危害的建议干预措施。本综述旨在确定减药是否为一种安全、有效且可行的干预措施,以改善老年人的死亡率和健康结局。
检索特定数据库,检索时间从建库至2015年2月。两名研究人员独立筛选所有检索到的文章以确定是否纳入,评估研究质量并提取数据。使用RevMan v5.3对数据进行汇总。符合条件的研究包括老年人至少停用一种药物的研究。主要结局为死亡率。次要结局为药物撤药不良事件、心理和身体健康结局、生活质量以及药物使用情况(如成功减药、开具的药物数量、潜在不适当药物使用)。
共有132篇论文符合纳入标准,包括34143名年龄为73.8±5.4岁的参与者。在非随机研究中,减药显示可显著降低死亡率(比值比0.32,95%置信区间:0.17 - 0.60)。然而,在随机研究中这一结果无统计学意义(比值比0.82,95%置信区间0.61 - 1.11)。亚组分析显示,针对个体患者的减药干预措施可显著降低死亡率(比值比0.62,95%置信区间0.43 - 0.88)。然而,一般性教育项目并未改变死亡率(比值比1.21,95%置信区间0.86 - 1.69)。
尽管非随机数据表明减药可降低死亡率,但随机研究未显示减药能改变死亡率。在随机研究中应用针对个体患者的减药干预措施时,死亡率显著降低。